Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: A randomized phase II study of the EORTC Gynecological Cancer Cooperative Group

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 86, Issue 2, 1999, Pages 179-183

  Pawinski, A ^a,e   Tumolo, S ^b   Hoesel, G ^c   Cervantes, A ^d   Van Oosterom, A T ^e   Hoctin Boes, G ^a   Pecorelli, S ^a,f  

^a EORTC DATA CENTER   (Belgium)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF VALENCIA   (Spain)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; IFOSFAMIDE;

ADENOCARCINOMA; ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENDOMETRIUM CANCER; FEMALE; HORMONAL THERAPY; HUMAN; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0032814609     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(99)00066-4     Document Type: Article

References (27)

1. Creasman W.T. Endometrial cancer. Limited disease: Role of surgery. Semin. Oncol. 21:1994;79-83.
2. Burke T.W., Wolfson A.H. Limited endometrial carcinoma: Adjuvant therapy. Semin. Oncol. 21:1994;84-90.
3. Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma. Acta Obstet. Gynecol. Scand. 63:1984;441-450.
4. Lentz S.S. Advanced and recurrent endometrial carcinoma: hormonal therapy. Semin. Oncol. 21:1994;100-106.
5. Thigpen T., Blessing J., Homesley H., et al. Phase III trial of Doxorubicin±Cisplatin in advanced or recurrent endometrial carcinoma: A GOG study. Proc. Am. Soc. Clin. Oncol. 12:1993;261.
6. Aapro M., Bolis G., Chevallier B., MelvandenBurg A. Poveda, A. Pawinski, An EORTC GCCG randomised phase II trial of Doxorubicin vs Doxorubicin+DDP in endometrial carcinoma. Proc. of ASCO. 13:1994;275.
7. WHO Handbook For Reporting Results of Cancer Treatment. 1979;WHO, Geneva.
8. R. Sylvester, A decision theoretic approach to the design of phase II clinical trials in cancer. ScD Thesis, Free University of Brussels, 1983.
9. Santoro A., Tursz T., Mouridsen H., Verweij J., Steward W., Somers R., Buesa J., Casali P., Spooner D., Rankin E. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 13:(7):1995;1537-1545.
10. Wexler L.H., Delaney T.F., Tsokos M., Avila N., Steinberg S.M., Weaver M.C., Clure L., Jacobson J., Jarosinski P., Hijazi Y.M., Balis F.M., Horowitz M.E. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer. 78:(4):1996;901-911.
11. Loehrer P.J., Lauer R., Roth B.J., Williams S.D., Kalasinski L.A., Einhorn L.H. Salvage therapy in recurrent germ cell cancer: Ifosfamid and cisplatin plus either VBL or VP-16. Ann. Int. Med. 109:1988;540-546.
12. Coiffier B. Ifosfamide in the treatment of lymphoma. Semin Oncol. 23:(3 Suppl 7):1996;2-7.
13. Loehrer P.J. The role of ifosfamide in small cell lung cancer. Semin Oncol. 23:(3 Suppl 7):1996;40-44.
14. Loehrer P.J. Current developments and future directions with Ifosfamide. Semin. Oncol. 16:(Suppl 3):1990;19-101.
15. Overmoyer B.A. Ifosfamide in the treatment of breast cancer. Semin Oncol. 23:(3 Suppl 6):1996;38-41.
16. Thigpen T., Lambuth B.W., Vance R.B. The role of Ifosfamide in gynecologic cancer. Semin. Oncol. 19:(Suppl 1):1994;30-34.
17. Barton C., Buxton E.J., Blackledge G., et al. A phase II study of IFOS in endometrial cancer. Cancer Chemother. Pharmacol. 26:1990;S4-S6.
18. Sutton G.P., Blessing J.A., Homesley H.D., McGuire W.P., Adcock L. Phase II study of Ifosfamide and Mesna in refractory adenocarcinoma of the endothelium. Cancer. 73:1994;1453-1455.
19. Bramwell V.H., Mouridsen H.T., Santoro A., Blackledge G., Somers R., Verweij J., Dombernowsky P., Onsrud M., Thomas D., Sylvester R. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. Cancer-Chemother Pharmacol. 31:(Suppl 2):1993;S180-S184.
20. Muggia F.M., Chia G., Reed L.J., Romney S.L. Doxorubicin-cyclophosphamide: Effective chemotherapy for advanced endometrial adenocarcinoma. J Obstet. Gynecol. 128:1977;314-319.
21. Horton J., Begg C.B., Arseneault J., Bruckner H., Creech R., Hahn R.G. Comparison of Adriamycin with Cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat. Rep. 62:1978;159-161.
22. Burke T.W., Gershenson D.M., Morris M., Stringer A., Levenback C., Tortolero-Luna G., Baker V.V. Postoperative adjuvant PAC chemotherapy in women with high risk endometrial carcinoma. Gynecol. Oncol. 55:1994;4750.
23. Campora E., Vidali A., Mammoliti S., et al. Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide. Eur J Gynecol. Oncol. 11:1990;181-183.
24. Thigpen T., Blessing J., DiSaia P., Ehrlich C. A randomised comparison of ADM with or without CYCLO in the treatment of advanced or recurrent endometrial carcinoma. Proc. ASCO. 4:1985;115.
25. Levin L., Hryniuk W. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin. Oncol. 14:(Supp 14):1987;12-19.
26. Van Oosterom A.T., Krzemieniecki K., Nielsen O.S., Judson I., Mouridsen H.T., Svancarova L., Wolld P. Spooner, C. Hermans, M. Van Glabbeke, J. Verweji, Randomised phase II study of the EORTC STBS group comparing two different IFOS regimens in chemotherapy untreated advanced soft tissue sarcoma patients. Proc. ASCO. 16:1997;496a.
27. Blackledge G., Buxton E.J., Mould J.J., Monaghan J., Paterson M., Tobias J., Alcock C., Meanwell C.A. Phase II studies of ifosfamide alone and in combination in cancer of the cervix. Cancer Chem. Pharmacol. 26:(Suppl):1990;S12-S16.